| 胃癌术后FOLFOX6方案与XELOX方案辅助化疗的生存比较 |
| |
| 引用本文： | 陈晓秋,刘楠楠. 胃癌术后FOLFOX6方案与XELOX方案辅助化疗的生存比较[J]. 中国肿瘤临床, 2014, 41(18): 1195-1198. DOI: 10.3969/j.issn.1000-8179.20140785 |
| |
| 作者姓名： | 陈晓秋 刘楠楠 |
| |
| 作者单位： | 北京大学深圳医院肿瘤内科(广东省深圳市 518036) |
| |
| 摘 要： | 目的 比较可切除胃癌患者术后分别采用奥沙利铂联合5-氟尿嘧啶/亚叶酸钙(FOLFOX6)与奥沙利铂联合卡培他滨(XELOX)两种方案辅助化疗的生存差异。 方法 147例Ⅰ~Ⅲ期胃癌术后(R0切除)患者接受治疗, 其中FOLFOX6组99例, XELOX组48例, 比较两组不良反应率和生存率。 结果 FOLFOX6组白细胞减少及肝功能异常的发生率明显高于XELOX组(P < 0.05), XELOX组手足综合征(HFS)的发生明显高于FOLFOX6组(P=0.016), 其它不良反应的比较, 包括贫血、血小板减少、恶心呕吐、腹泻、肾功能异常、外周神经毒性、口腔黏膜炎等差异无统计学意义(P＜0.05)。FOLFOX6组与XELOX组1、3、5年无病生存率(DFS)分别为81.7%、49.5%、39.8%和93.8%、52.1%、33.8%, 两组中位无病生存时间(mDFS)分别为35、38个月, 差异无统计学意义(P=0.672);FOLFOX6组与XELOX组1、3、5年总生存率(OS)分别为98.0%、68.1%、44.6%和97.8%、78.7%、44.7%, 两组中位总生存时间(mOS)分别为55、58个月, 比较亦无显著性差异(P=0.194)。 结论 两种化疗方案对胃癌患者远期生存的影响无显著性差异。
|
| 关 键 词： | 胃癌 辅助化疗 奥沙利铂 5-氟尿嘧啶 卡培他滨 生存率 |
| 收稿时间： | 2014-05-09 |
Comparison of patient survival on adjuvant FOLFOX6 and XELOX chemotherapy after resection for gastric cancer |
| |
| Affiliation: | Department of Oncology, Peking University Shenzhen Hospital, Shenzhen 518036, China |
| |
| Abstract: | Objective To compare the survival of resected gastric cancer patient treated with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX6) with those treated with oxaliplatin and capecitabine (XELOX). Methods A total of 147 resected gastric cancer patients accepted the treatment. Among them, 99 were treated with FOLFOX6 and 48 were treated with XELOX. Adverse events and survival rates of the two groups were compared. Results Incidence of leukopenia and hepatic dysfunction in the FOLFOX6 group was significantly higher than that of the XELOX group (P < 0.05), whereas hand-foot syndrome in the XELOX group was significantly higher than that of the FOLFOX6 group (P=0.016). By contrast, the incidence of other adverse events, such as anemia, thrombocytopenia, nausea and vomiting, diarrhea, kidney dysfunction, peripheral neurovirulence, and oral mucositis, was not significantly different (P＜0.05) between the two groups. After 1, 3, and 5 years, disease-free and overall survivals between the two groups were not significantly different (P＜0.05). Conclusion The effects of FOLFOX6 and XELOX adjuvant chemotherapies on long-term survival of resected gastric cancer patients were found to have no significant difference. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
